Hunan Key Laboratory of Oncotarget Gene and Clinical Laboratory, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University and Hunan Cancer Hospital, Changsha, 410013, China.
The First Clinical College of Traditional Chinese Medicine of Hunan University of Chinese Medicine, and Hunan Cancer Hospital, Changsha, 410007, China.
Cell Mol Biol Lett. 2024 Jun 28;29(1):92. doi: 10.1186/s11658-024-00607-4.
Nasopharyngeal carcinoma (NPC), primarily found in the southern region of China, is a malignant tumor known for its highly metastatic characteristics. The high mortality rates caused by the distant metastasis and disease recurrence remain unsolved clinical problems. In clinic, the berberine (BBR) compound has widely been in NPC therapy to decrease metastasis and disease recurrence, and BBR was documented as a main component with multiple anti-NPC effects. However, the mechanism by which BBR inhibits the growth and metastasis of nasopharyngeal carcinoma remains elusive. Herein, we show that BBR effectively inhibits the growth, metastasis, and invasion of NPC via inducing a specific super enhancer (SE). From a mechanistic perspective, the RNA sequencing (RNA-seq) results suggest that the RAS-RAF1-MEK1/2-ERK1/2 signaling pathway, activated by the epidermal growth factor receptor (EGFR), plays a significant role in BBR-induced autophagy in NPC. Blockading of autophagy markedly attenuated the effect of BBR-mediated NPC cell growth and metastasis inhibition. Notably, BBR increased the expression of EGFR by transcription, and knockout of EGFR significantly inhibited BBR-induced microtubule associated protein 1 light chain 3 (LC3)-II increase and p62 inhibition, proposing that EGFR plays a pivotal role in BBR-induced autophagy in NPC. Chromatin immunoprecipitation sequencing (ChIP-seq) results found that a specific SE existed only in NPC cells treated with BBR. This SE knockdown markedly repressed the expression of EGFR and phosphorylated EGFR (EGFR-p) and reversed the inhibition of BBR on NPC proliferation, metastasis, and invasion. Furthermore, BBR-specific SE may trigger autophagy by enhancing EGFR gene transcription, thereby upregulating the RAS-RAF1-MEK1/2-ERK1/2 signaling pathway. In addition, in vivo BBR effectively inhibited NPC cells growth and metastasis, following an increase LC3 and EGFR and a decrease p62. Collectively, this study identifies a novel BBR-special SE and established a new epigenetic paradigm, by which BBR regulates autophagy, inhibits proliferation, metastasis, and invasion. It provides a rationale for BBR application as the treatment regime in NPC therapy in future.
鼻咽癌(NPC)主要发生在中国南方地区,是一种具有高度转移性特征的恶性肿瘤。远处转移和疾病复发导致的高死亡率仍然是未解决的临床问题。在临床上,黄连素(BBR)化合物已广泛用于 NPC 治疗以减少转移和疾病复发,BBR 被记录为具有多种抗 NPC 作用的主要成分。然而,BBR 抑制鼻咽癌生长和转移的机制仍不清楚。在此,我们发现 BBR 通过诱导特定的超级增强子(SE)有效抑制 NPC 的生长、转移和侵袭。从机制上看,RNA 测序(RNA-seq)结果表明,表皮生长因子受体(EGFR)激活的 RAS-RAF1-MEK1/2-ERK1/2 信号通路在 BBR 诱导的 NPC 自噬中发挥重要作用。自噬阻断显著减弱了 BBR 介导的 NPC 细胞生长和转移抑制作用。值得注意的是,BBR 通过转录增加 EGFR 的表达,EGFR 敲除显著抑制了 BBR 诱导的微管相关蛋白 1 轻链 3(LC3)-II 增加和 p62 抑制,表明 EGFR 在 BBR 诱导的 NPC 自噬中发挥关键作用。染色质免疫沉淀测序(ChIP-seq)结果发现,只有在 BBR 处理的 NPC 细胞中才存在特定的 SE。该 SE 敲低显著抑制了 EGFR 和磷酸化 EGFR(EGFR-p)的表达,并逆转了 BBR 对 NPC 增殖、转移和侵袭的抑制作用。此外,BBR 特异性 SE 可能通过增强 EGFR 基因转录来触发自噬,从而上调 RAS-RAF1-MEK1/2-ERK1/2 信号通路。此外,体内 BBR 有效抑制 NPC 细胞生长和转移,LC3 和 EGFR 增加,p62 减少。总之,这项研究确定了一种新的 BBR 特异性 SE,并建立了一个新的表观遗传范例,即 BBR 通过调节自噬来抑制增殖、转移和侵袭。这为 BBR 在未来 NPC 治疗中的应用提供了依据。